Mayank Mamtani
Stock Analyst at B.Riley Financial
Total Price Targets
7
Stocks Covered
7
Sectors
Healthcare
Most Recent
Mar 4, 2026
Notable Calls (Last 12 Months)
Stocks Covered by Mayank Mamtani
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| TBPH | Theravance Biopharma Inc | $14.00 | $16.87 | -17.0% | 1 | Mar 4, 2026 |
| NVAX | Novavax, Inc. | $22.00 | $7.33 | +200.1% | 1 | Nov 18, 2024 |
| TRVI | Trevi Therapeutics, Inc. | $6.00 | $18.28 | -67.2% | 1 | Oct 4, 2024 |
| MGNX | MacroGenics, Inc. | $5.00 | $3.71 | +35.0% | 1 | Jul 31, 2024 |
| CYTK | Cytokinetics, Incorporated | $92.00 | $77.92 | +18.1% | 1 | Jun 4, 2024 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $270.00 | $465.94 | -42.1% | 1 | Mar 15, 2024 |
| TGTX | TG Therapeutics, Inc. | $11.50 | $52.02 | -77.9% | 1 | Apr 18, 2022 |
Recent Activity
- Mar 4, 2026— Set$14.00price target onTBPH(Theravance Biopharma Inc)
- Nov 18, 2024— Set$22.00price target onNVAX(Novavax, Inc.)
- Oct 4, 2024— Set$6.00price target onTRVI(Trevi Therapeutics, Inc.)
- Jul 31, 2024— Set$5.00price target onMGNX(MacroGenics, Inc.)
- Jun 4, 2024— Set$92.00price target onCYTK(Cytokinetics, Incorporated)
- Mar 15, 2024— Set$270.00price target onMDGL(Madrigal Pharmaceuticals, Inc.)
- Apr 18, 2022— Set$11.50price target onTGTX(TG Therapeutics, Inc.)
Frequently Asked Questions
Who is Mayank Mamtani?
Mayank Mamtani is a stock analyst at B.Riley Financial covering 7 stocks primarily in Healthcare. They have issued 7 price targets since Apr 18, 2022.
What stocks does Mayank Mamtani cover?
Mayank Mamtani currently covers 7 stocks, including TBPH, NVAX, TRVI, MGNX, CYTK.
What is Mayank Mamtani's latest price target?
Mayank Mamtani's most recent price target was $14.00 on TBPH (Theravance Biopharma Inc), set on Mar 4, 2026.
What is Mayank Mamtani's highest price target?
Mayank Mamtani's highest issued price target is $270.00 on MDGL, set on Mar 15, 2024.
More Analysts at B.Riley Financial
Coverage based on publicly published price targets. Not investment advice.